Hormonal
GLP-1 receptor agonists (specifically liraglutide) reduce cardiovascular events by preventing the progression of atherosclerosis, whereas SGLT2 inhibitors (empagliflozin) reduce mortality linked to cardiovascular events likely through hemodynamic and volume depletion effects rather than atherosclerosis modulation.
Understand that while both empagliflozin and liraglutide protect the heart, they may do so differently. Empagliflozin works quickly to reduce fluid load and heart stress (beneficial for heart failure), while liraglutide may work more slowly to protect blood vessels from plaque buildup. This distinction helps doctors choose the right drug for your specific heart condition.
In the LEADER trial... separation... suggests that liraglutide... may reduce the occurrence of cardiovascular events mainly by preventing progression of atherosclerosis... Unlike in the LEADER, such a rapid effect [in EMPA-REG] suggests treatment has little effect on the atherosclerotic process pointing for an effect unlikely to be mediated through the modulation of glucose or lipid metabolism.
Why this rating
Based on interpretation of trial curves and mechanistic speculation in the review.
Source
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
Angelo Avogaro et al. · Cardiovascular Diabetology · 2016
DOI 10.1186/s12933-016-0431-4
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →